Profile data is unavailable for this security.
About the company
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
- Revenue in HKD (TTM)6.07bn
- Net income in HKD744.56m
- Incorporated2010
- Employees3.55k
- LocationShanghai Henlius Biotech Inc11/F, B8 Building, No. 188 Yizhou Road,SHANGHAI 200233ChinaCHN
- Fax+86 2 134611802
- Websitehttps://www.henlius.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Shineway Pharmaceutical Group Ltd | 4.52bn | 1.19bn | 6.72bn | 3.23k | 5.17 | 0.8522 | 4.90 | 1.49 | 1.57 | 1.57 | 5.99 | 9.54 | 0.4476 | 1.28 | 5.26 | 1,315,967.00 | 11.76 | 8.03 | 15.47 | 9.77 | 75.21 | 74.55 | 26.27 | 17.87 | 3.14 | -- | 0.0457 | 36.29 | 14.32 | 11.94 | 34.14 | 13.89 | 0.6396 | 12.88 |
| Consun Pharmaceutical Group Ltd | 2.95bn | 899.49m | 6.97bn | 3.18k | 7.37 | 1.74 | 7.08 | 2.37 | 1.12 | 1.12 | 3.65 | 4.71 | 0.5209 | 2.00 | 12.89 | 941,976.20 | 15.97 | 12.04 | 23.24 | 19.25 | 74.22 | 74.55 | 30.66 | 24.89 | 2.80 | -- | 0.1144 | 40.84 | 10.71 | 7.03 | 14.88 | 11.01 | -22.93 | 18.43 |
| AIM Vaccine Co Ltd | 1.27bn | -1.28bn | 7.94bn | 1.56k | -- | 2.11 | -- | 6.24 | -1.06 | -1.06 | 1.05 | 3.11 | 0.1462 | 0.6325 | 1.10 | 784,166.60 | -22.69 | -- | -37.16 | -- | 72.34 | -- | -155.22 | -- | 0.6836 | -6.61 | 0.3437 | -- | -6.06 | -- | -307.07 | -- | -- | -- |
| Yichang Hec Changjiang Pharmactcl Co Ltd | 5.96bn | 1.77bn | 8.22bn | 4.89k | 4.64 | 0.882 | 4.00 | 1.38 | 2.01 | 2.01 | 6.77 | 10.59 | 0.4272 | 2.50 | 3.74 | 1,290,212.00 | 11.69 | 8.03 | 17.27 | 11.81 | 78.90 | 79.97 | 27.37 | 20.80 | 1.93 | 50.79 | 0.2126 | 15.81 | 68.08 | 20.18 | 2,501.24 | 16.15 | -11.50 | -- |
| Luye Pharma Group Ltd | 6.79bn | 828.57m | 9.59bn | 5.23k | 11.58 | 0.6851 | 5.75 | 1.41 | 0.2203 | 0.2203 | 1.80 | 3.72 | 0.236 | 2.44 | 3.02 | 1,288,372.00 | 3.11 | 2.80 | 5.47 | 4.45 | 68.73 | 70.53 | 13.18 | 10.39 | 1.20 | 3.14 | 0.4103 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
| Beijing Biostar Pharmaceuticals Co Ltd | -100.00bn | -100.00bn | 10.54bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 103.03 | -- | -18.15 | -- | -- | -- |
| China Traditional Chinese Med Hldg CoLtd | 18.50bn | 986.63m | 10.93bn | 17.72k | 11.08 | 0.4755 | 4.86 | 0.5906 | 0.1959 | 0.1959 | 3.67 | 4.56 | 0.453 | 1.54 | 1.82 | 1,069,290.00 | 2.62 | 4.60 | 4.01 | 7.07 | 49.86 | 57.07 | 5.77 | 9.77 | 1.51 | 7.39 | 0.1808 | 17.35 | 26.69 | 9.99 | 68.11 | -2.24 | -12.75 | -- |
| Shanghai Henlius Biotech Inc | 6.07bn | 744.56m | 11.01bn | 3.55k | 14.82 | 3.97 | 9.64 | 1.81 | 1.37 | 1.37 | 11.11 | 5.10 | 0.5764 | 1.90 | 6.82 | 1,667,847.00 | 7.07 | -8.59 | 14.25 | -14.14 | 73.23 | 71.77 | 12.27 | -27.37 | 0.329 | 7.60 | 0.6113 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| SSY Group Ltd | 6.47bn | 1.37bn | 11.03bn | 5.80k | 8.12 | 1.53 | 6.03 | 1.71 | 0.4593 | 0.4593 | 2.18 | 2.44 | 0.5418 | 2.75 | 3.07 | 1,155,141.00 | 11.54 | 10.51 | 14.88 | 14.03 | 54.39 | 58.72 | 21.30 | 18.62 | 2.06 | 28.65 | 0.323 | 38.56 | 0.4505 | 9.10 | 17.44 | 7.66 | 3.94 | 13.56 |
| Everest Medicines Ltd | 450.12m | -1.13bn | 12.29bn | 520.00 | -- | 2.55 | -- | 27.30 | -3.52 | -3.52 | 1.40 | 14.79 | 0.0756 | 5.23 | 3.22 | 1,041,948.00 | -19.03 | -30.52 | -20.21 | -33.14 | 75.74 | -- | -251.64 | -5,745.25 | 4.62 | -- | 0.1119 | -- | 884.46 | -- | -241.50 | -- | 4.65 | -- |
| 3SBio Inc | 9.06bn | 1.78bn | 13.22bn | 5.61k | 7.54 | 0.8548 | 5.97 | 1.46 | 0.7322 | 0.7322 | 3.72 | 6.46 | 0.3575 | 1.52 | 6.87 | 1,673,758.00 | 7.25 | 7.44 | 10.26 | 9.29 | 85.94 | 82.91 | 20.27 | 21.50 | 1.57 | 141.55 | 0.1998 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
| Grand Pharmaceutical Group Ltd | 10.59bn | 2.41bn | 15.41bn | 10.78k | 6.30 | 0.9801 | 5.36 | 1.46 | 0.6885 | 0.6885 | 3.03 | 4.43 | 0.4472 | 3.62 | 4.54 | 1,005,064.00 | 10.25 | 10.09 | 14.21 | 14.01 | 59.00 | 61.97 | 22.92 | 22.35 | 1.09 | -- | 0.2232 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
Data as of Nov 25 2024. Currency figures normalised to Shanghai Henlius Biotech Inc's reporting currency: Hong Kong Dollar HKD
11.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 07 Nov 2024 | 15.51m | 9.49% |
| Qatar Investment Authority (Investment Management)as of 09 May 2024 | 1.68m | 1.03% |
| Pictet Asset Management SAas of 30 Jun 2024 | 613.30k | 0.38% |
| Pictet Asset Management (Singapore) Pte Ltd.as of 30 Jun 2024 | 284.40k | 0.17% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 203.20k | 0.12% |
| SSgA Funds Management, Inc.as of 07 Nov 2024 | 151.40k | 0.09% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 90.00k | 0.06% |
| Dimensional Fund Advisors Ltd.as of 31 Aug 2024 | 15.91k | 0.01% |
| DFA Australia Ltd.as of 30 Sep 2024 | 13.22k | 0.01% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 07 Nov 2024Source: FactSet Research Systems Inc.
